

A **Meta-Analysis**¹ in critically ill patients confirms that when patients are provided with intravenous glutamine according to guidelines there are benefits in terms of:



Decreased hospital mortality risk
by 45 %



Reduced LOS* in ICU by 1,61 days
and hospital by 2,3 days



30 % Reduction in infectious
complication risk



Reduced duration of mechanical
ventilation by 1,56 days



100 mL Dipeptiven contains: 20 g Alanyl-Glutamine Dipeptide providing 13,46 g Glutamine to complete your parenteral nutrition while offering improved clinical outcomes.

*Remember to check the quantity of glutamine in your parenteral nutrition bag if applicable.

References:

1. Stehle P, Ellger B, Kojic D, et al. Clin Nutr ESPEN. 2017 Feb;17:75-85.

S3 Dipeptiven. Each 1 000 ml concentrate contains 200,0 g N(2)-L-alanyl-L-glutamine (82,0 g L-alanine & 134,6 g L-glutamine). Reg. No.: 33/23/0210
For full prescribing information refer to the latest professional information approved by the South African Health Products Regulatory Authority.

Fresenius Kabi South Africa (Pty) Ltd, Reg. No. 1998/006230/07
7 Kingfisher Avenue Midpoint, 162 Tonetti Street, Midrand
PO Box 4156, Halfway House 1685
Tel: + 27 11 545 0000 www.fresenius-kabi.co.za

PNB_145_2_2026_V1